ArticleMolecular therapy. Oncology2024

Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.

Catrin Heim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.